Flatlander schreef op 5 mei 2021 15:12:
"When do you think we w'll see something in the course that climbs"
I follow a number of MDx companies, all are trading well off of the 52 week high. Many of these companies are perceived to be associated with the shutdown. Wall St appears to be emphasizing re-opening plays right now. So MDx is out of the momentum crowds favor right now. Believe it or not, BCART is fairing better than most MDx sector stocks right now. I know BCART is not currently on the NYSE or NASDAQ but the US seems to set perceptions on which sectors are hot. My thesis in BCART is that they offer a means to automate MDx resulting in secular growth, so I'm less concerned with short term momentum flows.
AZN may start assisting with the placement of Idylla consoles during the 2nd half of this year but I suspect that two milestones will be necessary before this program can really ramp up, 1) the Tagrisso CDx will need EU approval. As I previously mentioned Idylla has an amplification curve issue with the EGFR T790 mutation which is important to the molecular pathway that Tagrisso utilizes.. BCART is working to improve the sensitivity for this mutation. I think we will see the improved combination assay next year. 2) the 2nd milestone is the gene fusion receiving IVD rather than RUO approval. Again I hope to see this play out within the next year.
So most of this in terms of increased cartridge sales is probably a 2022 and beyond story but BCART may start to see a benefit in terms of console placements at the end of this year.